

1 **TITLE**

2 **Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a**
3 **multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial**

4
5 Aydar A Ishmukhametov^{1,2}, Aleksandra A Siniugina¹, Nadezhda V Yagovkina³, Vladimir I Kuzubov⁴, Konstantin
6 A Zakharov⁵, Viktor P Volok^{1,6}, Maria S Dodina¹, Larissa V Gmyl¹, Natalya A Korotina¹, Rostislav D
7 Theodorovich¹, Yulia I Ulitina⁷, Andrey A Tsaan⁷, Tatiana V Pomaskina⁸, Anna V Kalenskaya⁹, Irina V
8 Solovjeva⁹, Elena V Tivanova⁹, Larissa Y Kondrasheva⁹, Antonina A Ploskireva⁹, Vasilij G Akimkin⁹, Ksenia A
9 Subbotina¹⁰, Georgy M Ignatyev¹, Anastasia K Korduban¹, Elena Y Shustova¹, Ekaterina O Bayurova¹, Alla S
10 Kondrashova¹, Darya V Avdoshina¹, Anastasia N Piniyeva¹, Anastasia A Kovpak¹, Liliya P Antonova¹, Yulia V
11 Rogova¹, Anna A Shishova^{1,2}, Yury Y Ivin¹, Svetlana E Sotskova¹, Konstantin A Chernov¹, Elena G Ipatova¹,
12 Ekaterina A Korduban¹, Liubov I Kozlovskaya^{1,2}, Ilya V Gordeychuk^{1,2,*}

13
14 ¹ Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of
15 Russian Academy of Sciences, 108819 Moscow, Russia; ishmukhametov@chumakovs.su (A.A.I.),
16 sinyugina@chumakovs.su (A.A.S.), volok_vp@chumakovs.su (V.P.V.), dodina_ms@chumakovs.su (M.S.D.),
17 gmyl_iv@chumakovs.su (L.V.G.), korotina_na@chumakovs.su (N.A.K.), teodorovich_rd@chumakovs.su
18 (R.D.T.), ignatjev_gm@chumakovs.su (G.M.I.), korduban_ak@chumakovs.su (A.K.K.),
19 shustova_eu@chumakovs.su (E.Y.S.); bayurova_eo@chumakovs.su (E.O.B.),
20 kondrashova_as@chumakovs.su (A.S.K.), avdoshina_dv@chumakovs.su (D.V.A.),
21 pinyaeva_an@chumakovs.su (A.N.P.), kovpak_aa@chumakovs.su (A.A.K.), antonova_lp@chumakovs.su
22 (L.P.A.), rogova_jv@chumakovs.su (Y.V.R.), shishova_aa@chumakovs.su (A.A.S.), ivin_uu@chumakovs.su
23 (Y.Y.I.); sotskova_se@chumakovs.su (S.E.S.), chernov@chumakovs.su (K.A.C.), ipatova_eq@chumakovs.su
24 (E.G.I.), e.korduban@gmail.com (E.A.K.), kozlovskaya_li@chumakovs.su (L.I.K.),
25 gordeychuk_iv@chumakovs.su (I.V.G.).

26 ² Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University,
27 Moscow, Russia;

28 ³ Kirov State Medical University of the Ministry of Health of Russia, Kirov, Russia; nad0511ya@rambler.ru (N.V.
29 Y.);

30 ⁴ Healthcare Unit No. 163 of Federal Medical Biological Agency of Russia, 630559, Novosibirsk region, Russia;
31 msch163@fmbamail.ru (V.I.K.),

32 ⁵ Eco-Safety Scientific Research Center, 196143, Saint-Petersburg, Russia; konstantin.zakharov@mail.ru (K.A.
33 Z.),

34 ⁶ Lomonosov Moscow State University, Moscow, Russia;

35 ⁷ RIC-Pharma, Moscow, Russia tsaan@ric-pharma.com (A.A.T.); shevchik.u@gmail.com (Y.I.U)

36 ⁸ Biopolis-Kirov 200, branch of the Chumakov Center for Research and Development of Immune-and-Biological
37 Products, Kirov, Russia; tania16may@gmail.com (T.V.P.)

38 ⁹ Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights
39 Protection and Human Wellbeing, 111123, Moscow, Russia; kalenskaya@cmd.su (A.V.K.),
40 solovieva_iv@cmd.su (I.V.S.), tivan@cmd.su (E.V.T.), kondrasheva@cmd.su (L.Y.K.), antoninna@mail.ru
41 (A.A.P.), vgakimkin@yandex.ru (V.G.A.)

42 ¹⁰ Perm State Medical University Ministry of Health of Russian Federation, Perm, Russia, ka.subbotina@bk.ru
43 (K.A.S.)

44 * Corresponding author

45
46 **Author contributions:**

47 Study concept and design — Aydar A Ishmukhametov, Aleksandra A Siniugina, Andrey A Tsaan, Ekaterina A
48 Korduban, Georgy M Ignatyev, Liubov I Kozlovskaya Ilya V Gordeychuk; acquisition of data — Nadezhda V
49 Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl,

50 Natalya A Korotina, Rostislav D Teodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V
51 Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G
52 Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O
53 Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Lilia P
54 Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin; analysis and interpretation of data — Aydar A
55 Ishmukhametov, Ekaterina Bayurova, Liubov I Kozlovskaya, Ilya V Gordeychuk; drafting of the manuscript —
56 Liubov I Kozlovskaya, Ilya V Gordeychuk, Alla S Kondrashova, Darya V Avdoshina; critical revision of the
57 manuscript for important intellectual content — Aydar A Ishmukhametov, Liubov I Kozlovskaya, Ilya V
58 Gordeychuk; statistical analysis — Andrey A Tsaan, Ksenia A Subbotina, Yulia I Ulitina, Liubov I Kozlovskaya;
59 obtained funding — Aydar A Ishmukhametov; administrative, technical, or material support — Aleksandra A
60 Siniugina, Anastasia K Korduban, Anastasia N Piniaeva, Ekaterina A Korduban, Elena G Ipatova, Georgy M
61 Ignatyev, Konstantin A Chernov, Konstantin A Zakharov, Nadezhda V Yagovkina, Svetlana E Sotskova, Tatiana
62 V Pomaskina, Vladimir I Kuzubov, Antonina A Ploskireva, Vasiliy G Akimkin; study supervision — Aydar A
63 Ishmukhametov, Aleksandra A Siniugina, Andrey A Tsaan, Ekaterina A Korduban.

64

65 **KEY WORDS:** COVID-19, inactivated vaccine, neutralizing antibodies, phase I-II clinical trials

66

67 **Corresponding author:**

68 Ilya Gordeychuk; address: premises 8, bldg. 1, Village of Institute of Poliomyelitis, Settlement “Moskovskiy”,
69 Moscow 108819, Russia; tel.: 7 495 531-01-70 add. 1035; fax: 7 495 841-93-21; gordeychuk_iv@chumakovs.su

70

71 **Conflict of interest statement:**

72 A.A.I., A.A.S., V.P.V., M.S.D., L.V.G., N.A.K., R.D.T., G.M.I., A.K.K., E.Y.S., E.O.B., A.S.K., D.V.A., A.N.P.,
73 A.A.K., L.P.A., Y.V.R., A.A.S., Y.Y.I., S.E.S., K.A.C, E.G.I., E.A.K., L.I.K. and I.V.G. are employees at the
74 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of
75 Russian Academy of Sciences, which developed and manufactured CoviVac

76

77 **Financial support:**

78 Study was funded by the Chumakov Federal Scientific Center for Research and Development of Immune-and-
79 Biological Products of Russian Academy of Sciences.

80 **ABSTRACT**

81 We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial of
82 the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified
83 coronavirus vaccine CoviVac in adult volunteers aged 18-60.

84 Safety of the vaccine was assessed in 398 volunteers who received two doses of the vaccine (n=298)
85 or placebo (n=100). The studied vaccine has shown good tolerability and safety. No deaths, serious
86 adverse events (AE), or other significant AE related to vaccination have been detected. The most
87 common AE in vaccinated participants was pain at the injection site ($p<0.05$).

88 Immunogenicity assessment was performed in 167 volunteers (122 vaccinated and 45 in Placebo
89 Group) separately for the participants who were anti-SARS-CoV-2 nAB negative (69/122 in Vaccine
90 Group and 28/45 in Placebo Group) or positive (53/122 in Vaccine Group and 17/45 in Placebo
91 Group) at screening.

92 At Day 42 after the first immunization the seroconversion rate in participants who were seronegative
93 at screening was 86.9% with average the geometric mean neutralizing antibody (nAB) titer of 1:20.
94 Statistically significant ($p<0.05$) increase of IFN- γ production by peptide-stimulated T-cells was
95 observed at Days 14 and 21 after the first immunization.

96 In participants who were seropositive at screening but had nAB titers below 1:256 the rate of 4-fold
97 increase in nAB levels was 85.2%, while in the participants with nAB titers $>1:256$ the rate of 4-fold
98 increase in nAB levels was below 45%. For the participants who were seropositive at screening the
99 second immunization did not lead to a significant increase in nAB titers.

100 In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with 86.9%
101 seroconversion rates in participants, who were seronegative at screening. In participants who were
102 seropositive at screening and had nAB titers below 1:256, a single immunization lead to a 4-fold
103 increase in nAB levels in 85.2% cases.

104 INTRODUCTION

105 The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute
106 respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed more than five million lives as of
107 November 2021 (WHO, 2021). In order to ensure the availability of the vaccines against COVID-19 to
108 every country in the world, all existing vaccine platforms and manufacturing capacities were
109 employed, including genetic (Baden et al., 2021; Polack et al., 2020), vectored (Falsey et al., 2021;
110 Logunov et al., 2021), subunit (Heath et al., 2021) and inactivated (Al Kaabi et al., 2021; Ella et al.,
111 2021; Zakarya et al., 2021; Zhang et al., 2021) vaccines etc.

112 Despite the strong immunogenicity and high short-term efficacy of the abovementioned approaches, it
113 has been shown that post-vaccination antibody levels decrease over time (Crawford et al., 2021;
114 Levin et al., 2021), which has led to implementation of annual and even semiannual booster
115 vaccinations in unfavorable epidemiological conditions in several countries, including Russia, setting
116 even greater demands for the safety profile of the vaccines used.

117 Despite generally lower post-vaccination neutralizing antibody (nAB) levels as compared to vectored
118 and mRNA vaccines, inactivated vaccines have been instrumental for prevention of severe cases of
119 COVID-19 with over 7 billion doses administered worldwide, showing exceptional safety (Ella et al.,
120 2021; Fadlyana et al., 2021).

121 We developed a β -propiolactone-inactivated whole virion vaccine CoviVac which has previously
122 shown no signs of acute/chronic, reproductive, embryo- and fetotoxicity, or teratogenic effects in the
123 antenatal and postnatal periods of development, as well as no allergenic properties in rodents and
124 nonhuman primates in preclinical trials (Kozlovskaya et al., 2021). Here, we report safety and
125 immunogenicity of CoviVac in a multicenter, randomized, double-blind, placebo-controlled phase I/II
126 clinical trial.

127

128 MATERIALS AND METHODS

129 Ethical approval

130 The study was conducted in accordance with the Declaration of Helsinki guidelines, ICH GCP and
131 Russian regulations. The study protocol (VKI-I/II-08/20) and its supplementary documentation were
132 approved by the Ethics Committee of the Ministry of Health of the Russian Federation (No. 502 from
133 September 21, 2020). Additionally, the protocol was approved by the local Ethics Committees of the
134 clinical sites, namely Kirov State Medical University of the Ministry of Health of Russia [No. 13/2020
135 from September 28, 2020]; Healthcare Unit No. 163 of FMBA of Russia, [No.1 from October 11,
136 2020]; Eco-Safety Scientific Research Center [No. 157 from October 1, 2020]. The study protocol was
137 registered at clinicaltrials.gov (ID NCT05046548).

138


139 Study design and participants

140 The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial of the
 141 tolerability, safety, and immunogenicity (Clinical trials, phase I/II) of the inactivated whole virion
 142 concentrated purified coronavirus vaccine CoviVac in adult volunteers aged 18-60.

143 Safety and immunogenicity assessment was performed in 3 consequent Stages: Stage 1 included the
 144 first 15 volunteers (10 inoculated with the vaccine and 5 with placebo with 14 days interval); Stage 2
 145 included 185 participants (140 inoculated with the vaccine and 45 with placebo) and started after the
 146 post-vaccination observation period in Stage 1; Stage 3 included 200 participants (150 inoculated with
 147 the vaccine and 50 with placebo) (Figure 1). Safety assessment was performed in Stages 1-3 and
 148 immunogenicity assessment was performed in Stage 3.

149 The study included participants from 18 to 60 years of age at the time of enrolment. During screening
 150 all participants were tested for SARS-CoV-2 infection by PCR in nasopharyngeal swabs. The
 151 participants of Stages 1 and 2 were also screened at enrolment for anti-SARS-CoV-2 IgM and IgG
 152 antibodies by ELISA. Individuals positive in either test were not included. The participants of Stage 3
 153 were included regardless of their SARS-CoV-2 IgM and IgG status at enrolment. Persons with history
 154 of SARS-CoV-1, SARS-CoV-2, or MERS infection, confirmed contact with COVID-19 patients,
 155 previous severe allergic reactions, tuberculosis, cancer, mental or autoimmune diseases were also
 156 not included. All participants were screened for eligibility on the basis of their health status, including
 157 their medical history, vital signs, physical examination and laboratory test results, and were enrolled
 158 after providing signed and dated informed consent forms. Details of the inclusion, non-inclusion and
 159 exclusion criteria can be found in the study protocol (clinicaltrials.gov ID NCT05046548).

160



161

162 **Figure 1.** Study profile. Horizontal light grey lines represent the Stages of the study. Dotted lines
163 represent exclusion of the participants from a given Stage of the study.

164

165 **Randomization and masking**

166 Randomization was performed using the sealed envelope method at the day of the 1st immunization.
167 Distribution of the participants into the Vaccine Group or the Placebo Group was carried out using
168 random number generator software.

169 After assigning a three-digit randomization number to a participant, a sealed envelope with the
170 randomization number was given to a healthcare worker who administered the vaccine. The
171 participants did not know which preparation they were receiving. After the vaccination, a separate
172 physician observed the participant for possible adverse events (AE). The laboratory specialists were
173 provided with the samples marked with coded numbers, and thus were also blinded.

174

175 **Procedures**

176 CoviVac vaccine (manufactured by the Chumakov FSC R&D IBP RAS as described previously
177 (Kozlovskaya et al., 2021)) is a whole virion β -propiolactone inactivated concentrated purified vaccine
178 prepared in Vero cells and supplemented with aluminum hydroxide. Placebo preparation contained
179 buffer saline used in the vaccine preparation and the equivalent amount of aluminum hydroxide.

180 Preparations were provided as single dose (0.5 ml) vials with sterile liquid that was injected
181 intramuscularly into deltoid muscle in a two-dose schedule with 14 days interval. Participants were
182 observed for any immediate AEs for 30 min following the administration of each dose, and then daily
183 until Day 15-17 (1-3 days after the 2nd vaccination), with subsequent follow-up visits at Days 20 (only
184 for Stages 1 and 2), 27-30 and 42-45 (for all Stages). AEs were self-recorded by participants in
185 diaries. During the visits, vital signs measurement and physical examination were performed.
186 Neurological assessment was performed before each vaccination, 3 days after each vaccination and
187 28 days after the 2nd vaccination. Urine and blood samples were collected at screening and days 3, 7,
188 10, 14, 17, 20, 27 and 42 after the 1st vaccination for hematological and biochemical analysis and
189 immunological tests (at Stage 3). ECG was carried out at screening and once at day 2-6 after the 1st
190 vaccination.

191

192 **Safety assessment**

193 AEs were monitored until Day 42-45 after the 1st vaccination (Day 28-31 after the 2nd vaccination).
194 The solicited local AEs were pain, indurations, hematomas, swelling, itching and hypersensitivity at
195 the injection site, and solicited systemic AEs were fever, fatigue or malaise, nervous system disorders
196 (headache, lightheadedness), musculoskeletal and connective tissue disorders (arthralgia, myalgia),
197 disorders of respiratory system and mediastinal organs (pain/sore throat, nasal congestion,

198 rhinorrhea, cough, shortness of breath), gastrointestinal tract disorders (nausea, vomiting, diarrhea,
199 impaired appetite). All unsolicited AEs were reported by participants throughout the study.

200 AEs were graded as mild, moderate or severe according to the severity scoring chart (Supplementary
201 Table 1) and assessed for the probability of their relation to the tested vaccine (highly
202 probable/certain, probable, possible, unlikely, unrelated, unknown).

203

204 **Immunogenicity assessment**

205 Humoral immunity against SARS-CoV-2 was assessed in serum samples using chemiluminescent
206 microparticle immunoassays (CMIA) and virus neutralization test (NT).

207 IgG antibodies to nucleocapsid protein (N) were detected using Architect SARS-CoV-2 IgG CMIA
208 (Abbott Diagnostics, USA). IgG antibodies to receptor-binding domain (RBD) of the spike protein (S)
209 were detected using Access SARS-CoV-2 IgG CMIA (Beckman, USA).

210 Serum samples from randomly selected participants were additionally tested in ELISA for total
211 antibodies against RBD with CoronaPass Total (Genetico, Russia) and for total antibodies to S
212 protein trimer (Vector-Best, Russia).

213 Neutralization test was performed using SARS-CoV-2 strain PIK35 in Vero cells as described
214 previously (Kozlovskaya et al., 2021). Serum samples that did not show neutralization in 1:8 dilution
215 were considered negative. Immunogenicity assessment was performed in 167 participants of Stage 3.

216 Interferon-gamma (IFN- γ) production in response to stimulation with SARS-CoV-2 S-protein peptides
217 was assessed using QuantiFERON SARS-CoV-2 Starter Set (Qiagen, Germany), using two SARS-
218 CoV-2 S protein peptide pools (Ag1 and Ag2) designed to stimulate the production of IFN- γ by S-
219 protein-specific CD4 (Ag1) and CD4/CD8 (Ag2) T cells, which was detected by ELISA according to
220 the manufacturer's protocol. A Mitogen tube served as positive control. The baseline IFN- γ level in the
221 Nil tube (unstimulated lymphocytes) was subtracted from the IFN- γ level in the antigen tubes and the
222 Mitogen tube to correct for background or non-specific IFN- γ signal. The results were reported in
223 international units of IFN- γ per milliliter of whole blood (IU/mL) using a dilution curve of the standard
224 supplied with the kit. Calibration curve was generated at each assay run. Samples were considered
225 reactive for an IFN- γ response if the IFN- γ levels obtained from the tubes with stimulus were 0.01
226 IU/mL above baseline levels obtained from the unstimulated control.

227

228 **Outcomes**

229 The primary endpoints for safety assessment were the frequency and severity of AEs within the
230 observation period (72 h, 7 days after each vaccination and 28 days after the 2nd vaccination). The
231 primary immunogenicity endpoints were the geometric mean nAB titer (GMT) and seroconversion rate
232 (the percentage of volunteers with 4-fold increase in GMT) 28 days after the 2nd vaccination.
233 Secondary endpoints included seroconversion rates at Days 7 and 14 and Months 2, 3, 4, 5 and 6
234 after the 2nd vaccination.

235

236 **Statistical analysis**

237 The sample size was determined based on the requirements of the national guidelines, and the
238 distribution of the participants between Vaccine Group and Placebo Group was 3:1.

239 All parameters were evaluated using descriptive statistics (mean, standard deviation, percentile,
240 medians, min and max). All efficacy parameters are presented as mean with 95% confidence interval
241 (CI). Value comparisons (for example, GMT) were made using ANOVA or Mann-Whitney tests. P
242 values below 0.05 (two-sided) were considered to be significant. Frequencies (%) were compared
243 with Chi-square test or Fisher's exact test. Analysis of variance or Friedman's analysis were used for
244 comparisons of the parameters over time. Spearman's rank correlation coefficient was used for
245 correlation analysis.

246

247 **RESULTS**

248 **Demographic and anthropometric data**

249 Study profile is presented in Figure 1. Overall, starting from October 3, 2020, 498 volunteers were
250 screened for eligibility at three clinical sites. Based on clinical, laboratory and instrumental
251 examinations, 400 volunteers aged 18-60 years were enrolled in the study. All enrolled participants
252 were considered healthy and had no previous or current diagnosed comorbid conditions. All
253 participants were randomized by the sealed envelope method into 2 groups: 300 participants were
254 assigned to receive the vaccine and 100 participants were assigned to receive placebo (2 injections,
255 0.5 ml, 14 days interval for both the vaccine and placebo).

256 Two out of 300 participants from the Vaccine Group withdrew consent prior to administration of the 1st
257 dose. Thus, safety assessment was performed in 398 (298 in the Vaccine Group and 100 in the
258 Placebo Group) participants of the study. Participants who contracted SARS-CoV-2 infection during
259 the observation period were not excluded from safety assessment.

260 Out of 200 (150 in the Vaccine Group and 50 in the Placebo Group) participants initially included into
261 Stage 3 for immunogenicity assessment, a total of 33 (28 from the Vaccine Group and 5 from the
262 Placebo Group) were excluded during the observation period as they contracted SARS-CoV-2
263 infection or withdrew consent. Thus, immunogenicity assessment was performed in 167 (122 in the
264 Vaccine Group and 45 in the Placebo Group) participants of Stage 3.

265 The demographic characteristics of the participants in the safety and immunogenicity assessment
266 populations were similar across treatment groups in terms of sex, age, and BMI (Table 1). The mean
267 age of the study participants was 33.1 and 33.5 years, the female/male proportion was 36.9/63.1 and
268 34/66, and mean body mass index (BMI) was 23.8 and 24 kg/m² for the Vaccine Group and the
269 Placebo Group, correspondingly.

270

271 **Table 1.** Demographic and anthropometric characteristics of the participants of the clinical trial

n (%)

		Total	Vaccine	Placebo
Safety assessment (Stages 1-3)				
No. of participants		398	298	100
Age, years	Mean ± SD	33.2 ± 11.8	33.1 ± 11.8	33.5 ± 12.1
	18-29	195 (49.0)	149 (50.0)	46 (46)
	30-39	75 (18.9)	55 (18.5)	20 (20)
	40-49	83 (20.9)	61 (20.4)	22 (22)
	50-60	45 (11.3)	33 (11.1)	12 (12)
Sex	F	144 (36.2)	110 (36.9)	34 (34)
	M	254 (63.8)	188 (63.1)	66 (66)
BMI, kg/m ²	Mean ± SD	23.9 ± 2.8	23.8 ± 2.8	24.0 ± 2.7
	18-25	260 (65.3)	197 (66.1)	63 (63)
	25.1-30	138 (34.7)	101 (33.9)	37 (37)
Immunogenicity assessment (Stage 3)				
No. of participants		167	122	45
Age, years	Mean ± SD	34.4 ± 12.9	34.6 ± 12.9	33.6 ± 13.3
	18-29	76 (45.5)	55 (45.1)	21 (46.7)
	30-39	28 (16.8)	19 (15.6)	9 (20.0)
	40-49	39 (23.4)	30 (24.6)	9 (20.0)
	50-60	24 (14.3)	18 (14.7)	6 (13.3)
Sex	F	61 (36.5)	46 (37.7)	15 (33.3)
	M	106 (63.5)	76 (63.3)	30 (66.7)
BMI, kg/m ²	Mean ± SD	24.1 ± 2.7	24.1 ± 3.2	24.1 ± 2.7
	18-25	104 (62.3)	75 (61.5)	29 (64.4)
	25.1-30	63 (37.7)	47 (38.5)	16 (35.6)

272

273 **Tolerance, reactogenicity and safety**

274 In this trial, participants were monitored for AEs until Day 42-45 after the 1st vaccination (Day 28-31
 275 after the 2nd vaccination). The studied vaccine has shown good tolerability and safety. No deaths,
 276 serious AEs, or other significant AEs related to vaccination have been reported. All observed severe
 277 adverse events (SAEs) were classified as unlikely to be related or unrelated to the tested vaccine.

278 In total, during the study period, 244 AEs were recorded in 136 (34.2 %) participants, of which 189
 279 AEs were observed in 105 (35.2%) of Vaccine Group participants, and 55 AEs in 31 (31%) of Placebo
 280 Group participants (Table 2, Supplementary Table S2, Supplementary Table S3).

281 The most common AE in Vaccine Group was pain at the injection site. It was registered in the
 282 Placebo Group as well, but was significantly less common (P<0.05).

283 Changes in the parameters of clinical blood tests, biochemical blood tests and general urine analysis,
 284 observed at different time points, in most cases were regarded as clinically insignificant and unrelated
 285 to vaccination (Supplementary Table S2, Supplementary Table S3). Clinically significant deviations in
 286 the parameters of creatine phosphokinase, ALT, AST, CRP and leukocytes were observed in both
 287 groups and their frequencies did not differ between the study groups. No clinically significant
 288 deviations in the parameters evaluated during physical examination, neurological status and ECG
 289 were observed in both groups.

290 One participant (0.3%, 0.1–1.9 95% CI) from the Vaccine Group died at Day 29 of the observation
 291 period as a result of acute circulatory disorder. Autopsy examination revealed signs of chronic mild
 292 hepatitis, pre-existing stromal atherosclerosis and dilated cardiomyopathy manifested by myocardial

293 hypertrophy. The character of the lesions observed at histological examination indicated long-lasting
294 pathology of the myocardium. As the participant had no clinically significant deviations in any of the
295 clinical parameters throughout the observation period, including physical condition, body temperature,
296 vital signs, urine analysis, biochemical parameters of blood, complete blood count, coagulation
297 parameters and ECG, and had no local or systemic reactions after each immunization, the relation of
298 this SAE to vaccination was classified by the treating physician as unlikely.
299

Table 2. Severity of adverse events observed in the Vaccine Group and in the Placebo Group within 28 days following each vaccination

Adverse event	Score	Vaccine n (%; 95% CI)			Placebo n (%; 95% CI)		
		Total participants N=298	After		Total participants N=100	After	
			V1	V2		V1	V1
Local and systemic reactions	Mild	57 (19.1%, 15.1–24.0%) / 80	33 (11.1%, 8.0–15.1%) / 37	34 (11.4%, 8.3–15.5%) / 43	16 (16%, 10.1–24.4%) / 23	7 (7%, 3.4–13.7%) / 8	10 (10%, 5.5–17.4%) / 15
	Moderate	3 (1%, 0.3–2.9%) / 3	2 (0.7%, 0.2–2.4%) / 2	1 (0.3%, 0.1–1.9%) / 1			
	Severe	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1			
Pain at the injection site	Mild	47 (15.8%, 12.1–20.3%) / 55 *	30 (10.1%, 7.1–14.0%) / 30	25 (8.4%, 5.7–12.1%) / 25	11 (11%, 6.3–18.6%) / 12 *	5 (5%, 2.2–11.2%) / 5	7 (7%, 3.4–13.7%) / 7
	Moderate	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1				
Induration at the injection site	Mild	3 (1%, 0.3–2.9%) / 3	1 (0.3%, 0.1–1.9%) / 1	2 (0.7%, 0.2–2.4%) / 2	3 (3%, 1.0–8.5%) / 3	-	3 (3%, 1.0–8.5%) / 3
Hematoma at the injection site	Mild	-	-	-	1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
Swelling at the injection site	Mild				1 (1%, 0.2–5.4%) / 1		1 (1%, 0.2–5.4%) / 1
Itching at the injection site	Mild				1 (1%, 0.2–5.4%) / 1		1 (1%, 0.2–5.4%) / 1
Fever	Mild	11 (3.7%, 2.1–6.5%) / 12	5 (1.7%, 0.7–3.9%) / 5	6 (2%, 0.9–4.3%) / 7	2 (2%, 0.6–7.0%) / 2	2 (2%, 0.6–7.0%) / 2	-
	Moderate	2 (0.7%, 0.2–2.4%) / 2	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Malaise	Mild	4 (1.3%, 0.5–3.4%) / 10	1 (0.3%, 0.1–1.9%) / 1	3 (1%, 0.3–2.9%) / 9	2 (2%, 0.6–7.0%) / 3	-	2 (2%, 0.6–7.0%) / 3
	Severe	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Laboratory methods	Mild	19 (6.4%, 4.1–9.7%) / 22	7 (2.3%, 1.1–4.8%) / 7	12 (4%) / 15	7 (7%, 3.4–13.7%) / 7	2 (2%, 0.6–7.0%) / 2	5 (5%, 2.2–11.2%) / 5
	Moderate	3 (1%, 0.3–2.9%) / 3	1 (0.3%, 0.1–1.9%) / 1	2 (0.7%, 0.2–2.4%) / 2			
Increased leukocytes content	Moderate	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Positive SARS-CoV-2 PCR test	Mild	17 (5.7%, 3.6–8.9%) / 17	7 (2.3%, 1.1–4.8%) / 7	10 (3.4%, 1.8–6.1%) / 10	6 (6%, 2.8–12.5%) / 6	2 (2%, 0.6–7.0%) / 2	4 (4%, 1.6–9.8%) / 4
	Moderate	2 (0.7%, 0.2–2.4%) / 2		2 (0.7%, 0.2–2.4%) / 2			
Increased creatine phosphokinase level	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1			
	Moderate	2 (0.7%, 0.2–2.4%) / 2		2 (0.7%, 0.2–2.4%) / 2	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Increased ALT level	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Increased AST level	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Increased CRP level	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Blood and lymphatic system disorders	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Inguinal lymphadenitis	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Blood vessel disorders					1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
Deep venous leg thrombosis	Moderate	-	-	-	1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
Infections and parasitic invasions	Mild	22 (7.4%, 4.9–10.9%) / 22	15 (5%, 2.2–11.2%) / 15	7 (2.3%, 1.1–4.8%) / 7	3 (3%, 1.0–8.5%) / 3	2 (2%, 0.6–7.0%) / 2	1 (1%, 0.2–5.4%) / 1
	Moderate	7 (2.3%, 1.1–4.8%) / 7	3 (1%, 0.3–2.9%) / 3	4 (1.3%, 0.5–3.4%) / 4			
	Severe				1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
SARS-CoV-2 infection	Mild	20 (6.7%, 4.4–10.1%) / 20	14 (4.7%, 2.8–7.7%) / 14	6 (2%, 0.9–4.3%) / 6	3 (3%, 1.0–8.5%) / 3	2 (2%, 0.6–7.0%) / 2	1 (1%, 0.2–5.4%) / 1
	Moderate	5 (1.7%, 0.7–3.9%) / 5	2 (0.7%, 0.2–2.4%) / 2	3 (1%, 0.3–2.9%) / 3	-	-	-
	Severe	-	-	-	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Candidiasis	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Other upper respiratory tract infections	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
	Moderate	2 (0.7%, 0.2–2.4%) / 2	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1			
Nervous system disorders	Mild	11 (3.7%, 2.1–6.5%) / 20	4 (1.3%, 0.5–3.4%) / 4	9 (3%, 1.6–5.6%) / 16	6 (6%, 2.8–12.5%) / 12	3 (3%, 1.0–8.5%) / 3	3 (3%, 1.0–8.5%) / 9
Headache	Mild	11 (3.7%, 2.1–6.5%) / 19	4 (1.3%, 0.5–3.4%) / 4	8 (2.7%, 1.4–5.2%) / 15	6 (6%, 2.8–12.5%) / 12	3 (3%, 1.0–8.5%) / 3	3 (3%, 1.0–8.5%) / 9
Dizziness	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Musculoskeletal and connective tissue disorders	Mild	4 (1.3%, 0.5–3.4%) / 6	2 (0.7%, 0.2–2.4%) / 3	2 (0.7%, 0.2–2.4%) / 3			
	Moderate	1 (0.3%, 0.1–1.9%) / 1		1 (0.3%, 0.1–1.9%) / 2	1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
	Mild	2 (0.7%, 0.2–2.4%) / 2	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Arthralgia	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Lumbar pain	Moderate	-	-	-	1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
Myalgia	Mild	4 (1.3%, 0.5–3.4%) / 4	2 (0.7%, 0.2–2.4%) / 2	2 (0.7%, 0.2–2.4%) / 2	-	-	-
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Gastrointestinal tract disorders	Mild	3 (1%, 0.3–2.9%) / 3	1 (0.3%, 0.1–1.9%) / 1	2 (0.7%, 0.2–2.4%) / 2	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1			

Adverse event	Score	Vaccine n (% , 95% CI)			Placebo n (% , 95% CI)		
		Total participants N=298	After		Total participants N=100	After	
			V1	V2		V1	V1
Diarrhea	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Pyrosis	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Nausea	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Hearing disorders	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Ear congestion	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Disorders of respiratory system and mediastinal organs	Mild	6 (2%, 0.9–4.3%) / 6	2 (0.7%, 0.2–2.4%) / 2	4 (1.3%, 0.5–3.4%) / 4	3 (3%, 1.0–8.5%) / 5	1 (1%, 0.2–5.4%) / 1	2 (2%, 0.6–7.0%) / 4
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Throat pain	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	1 (1%, 0.2–5.4%) / 2	-	1 (1%, 0.2–5.4%) / 2
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Pain in the oropharynx	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Cough	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Impaired sense of smell	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	-	-	-
Dyspnea	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Sore throat	Mild	1 (0.3%, 0.1–1.9%) / 1	1 (0.3%, 0.1–1.9%) / 1	-	1 (1%, 0.2–5.4%) / 1	1 (1%, 0.2–5.4%) / 1	-
	Mild	2 (0.7%, 0.2–2.4%) / 8	-	2 (0.7%, 0.2–2.4%) / 8	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Metabolic disorders	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
	Mild	2 (0.7%, 0.2–2.4%) / 8	-	2 (0.7%, 0.2–2.4%) / 8	1 (1%, 0.2–5.4%) / 1	-	1 (1%, 0.2–5.4%) / 1
Impaired appetite	Mild	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
	Moderate	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Other	Severe	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-
Death from acute circulatory disorder**	Severe	1 (0.3%, 0.1–1.9%) / 1	-	1 (0.3%, 0.1–1.9%) / 1	-	-	-

301 * Differences are statistically significant (P<0.05)

302 ** Relation to vaccination classified as unlikely by the treating physician

303

304

305 Selection of the method of humoral immunity assessment

306 To determine the optimal method of anti-SARS-CoV-2 humoral immunogenicity assessment we
 307 compared the neutralizing antibody (nAB) detection rates in NT with two commercial CMIA tests
 308 commonly used for the screening of anti-N protein IgG (Architect SARS-CoV-2 IgG, Abbott
 309 Diagnostics, USA) and anti-RBD IgG (Access SARS-CoV-2 IgG, Beckman, USA). We used NT and
 310 both CMIA tests to analyze serum samples from all 167 participants (122 from the Vaccine Group and
 311 45 from the Placebo Group) included in Stage 3, obtained at screening and at Days 7, 14, 21, 28 and
 312 42 after the 1st immunization (Table 3). The analysis included both the participants who were anti-
 313 SARS-CoV-2 nAB negative (69/122 in Vaccine Group and 28/45 in Placebo Group) and anti-SARS-
 314 CoV-2 nAB positive (53/122 in Vaccine Group and 17/45 in Placebo Group) at screening.

315 There was no significant correlation between seropositivity rates assessed by NT and CMIA at all time
 316 points (Table 3).

317

318 **Table 4.** Percent of participants with detectable anti-SARS-CoV-2 antibodies in NT and CMIA at
 319 different time points after the first vaccination

Group	N	Test	Positive (% , 95% CI)					
			Screening	Day 7	Day 14	Day 21 (7 days after the 2 nd vaccination)	Day 28 (14 days after the 2 nd vaccination)	Day 42 (28 days after the 2 nd vaccination)
Vaccine	122	nAB (NT)	53 (43.4, 35.0– 52.3)	68 (55.7, 46.9– 64.2)	92 (75.4, 67.1– 82.2)	112 (91.8, 85.6– 95.5)	112 (91.8, 85.6– 95.5)	113 (92.6, 86.6– 96.1)
	101	anti-RBD IgG (Beckman)	28 (28, 20.1– 37.5) ¹	33 (32.7, 24.3– 42.3)	43 (42.6, 33.4– 52.3)	44 (44.9, 35.4– 54.8) ²	47 (46.5, 37.1– 56.2)	44 (43.6, 34.3– 53.3)
	101	anti-N IgG (Abbot)	24 (24, 16.7– 33.2) ¹	28 (27.7, 19.9– 37.1)	34 (33.7, 25.2– 43.3)	43 (43.9, 34.5– 53.7) ²	57 (56.4, 46.7– 65.7)	56 (55.4, 45.7– 64.8)
Placebo	45	nAB (NT)	17 (37.8, 25.1– 52.4)	18 (40.0, 27.0– 54.6)	19 (42.2, 29.0– 56.7)	17 (38.6, 25.7– 53.4) ³	17 (37.8, 25.1– 52.4)	18 (40.9, 27.7– 55.6) ³
	36	anti-RBD IgG (Beckman)	10 (27.8, 15.8– 44)	11 (30.6, 18– 46.9)	11 (30.6, 18– 46.9)	11 (30.6, 18–46.9)	11 (30.6, 18–46.9)	9 (25, 13.8–41.1)
	36	anti-N IgG (Abbot)	10 (27.8, 15.8– 44)	10 (27.8, 15.8– 44)	8 (22.2, 11.7– 38.1)	9 (25, 13.8–41.1)	8 (22.2, 11.7– 38.1)	8 (22.2, 11.7– 38.1)


320 ¹ N = 100; ² N = 98; ³ N = 44

321

322 Therefore, further in order to assess the sensitivity of commercial CMIA and ELISA tests, serum
 323 samples from 27 randomly selected participants from the Vaccine Group in Stage 3 who were anti-
 324 SARS-CoV-2 nAB negative at screening were used to evaluate the correlation between the virus
 325 neutralization titers in NT and the positivity coefficients in binding antibody detection assays. Two
 326 abovementioned CMIA tests and two ELISA-based tests detecting total antibodies to S trimer
 327 expressed in eukaryotic system and total antibodies to RBD (SARS-CoV-2-AB total-EIA-BEST,
 328 Vector-Best, Russia and CoronaPass Total kit, Genetico, Russia, respectively) were used (Figure 2).

329 Both ELISA-based total antibody detection kits showed higher correlation of seropositivity rates and
 330 positivity coefficients with the virus neutralization titers in NT than the CMIA tests. The Vector-Best

331 ELISA kit was able to detect total antibodies to S trimer in 3/27 participants at Day 14 after the 1st
332 immunization (Figure 2B), while virus-neutralizing antibodies in NT (Figure 2A) and total antibodies to
333 RBD (Figure 2C) were detected only from Day 21.
334 The analysis of the individual test results showed that in the samples with detectable nAB levels we
335 could see a statistically significant increase in the positivity coefficients in CMIA kits compared with
336 the samples obtained at screening (Figure 3 A,D,E), but the levels were below the “grey zone”,
337 indicating insufficient sensitivity of these tests. Thus, we did not find a strong correlation between the
338 results of NT and the results of CMIA and ELISA tests (Figure 3E), and only NT results were used for
339 further calculations of seroconversion rates.
340



341
342 **Figure 2.** Anti-SARS-CoV-2 antibody levels following immunization of 27 randomly selected
343 participants who were seronegative at screening. nAB titers in NT (A); and positivity coefficients for
344 ELISA and CMIA kits: anti-S trimer total antibodies ELISA (Vector-Best) (B); anti-RBD total antibodies
345 ELISA (CoronaPass) (C); anti-RBD IgG CMIA (Beckman) (D); and anti-N IgG CMIA (Abbot) (E). Black

346 line – Mean, whiskers – SD. Blue area signifies a positive threshold (grey zone) for each test. Black
347 dots represent the results from sera samples from 6 randomly selected participants from Placebo
348 Group obtained in the same tests in parallel (with Vector-Best sera from 3 participants were tested).
349 Purple dots represent 4 samples of convalescent sera used as positive controls.

350

351 **CoviVac humoral immunogenicity assessment (NT)**

352


353 Immunogenicity assessment was separately performed for the participants who were anti-SARS-CoV-
354 2 nAB negative (69/122 in Vaccine Group and 28/45 in Placebo Group) or anti-SARS-CoV-2 nAB
355 positive (53/122 in Vaccine Group and 17/45 in Placebo Group) at screening.

356 Participants with undetectable anti-SARS-CoV-2 antibodies at screening (with any method) showed
357 increasing nAB titers and seroconversion from day 7 post 1st vaccination (Figure 3A). By Day 7 after
358 the 2nd vaccination (21 days total) the seroconversion rate reached 84.1% and did not decrease
359 during the period of observation (until Day 28 post 2nd vaccination, Figure 3B). GMT of nABs peaked
360 at Day 21 after the 1st vaccination and did not decrease significantly during the period of observation
361 (Figure 3A). Among the participants, who did not have detectable anti-SARS-CoV-2 nAB antibodies at
362 screening, nABs were detected in 0/69 (0%), 15/69 (21.7%), 40/69 (57.9%), 58/69 (84.1%), 59/69
363 (85.5%) and 60/69 (86.9%) at screening, Days 7, 14, 21, 28 and 42, respectively. The GMT in positive
364 samples at Days 7, 14, 21, 28 and 42 was 1:2, 1:4, 1:10, 1:15 and 1:20, respectively (Figure 3 A, B).

365 According to the protocol of the clinical trial, seroconversion for participants who had detectable
366 SARS-CoV-2 nABs at screening was defined as 4-fold increase of nAB titers after vaccination
367 compared to baseline titers.

368 Participants who had detectable antibodies against SARS-CoV-2 at screening showed increased nAB
369 titers at days 7 and 14 post 1st vaccination. However, after the 2nd vaccination the titers did not
370 increase significantly (Figure 3C). Moreover, vaccination of the participants with lower nAB titers
371 (below 1:256) had a more pronounced effect of titer increase (4-fold and more), whereas we observed
372 almost no booster effect in participants with high baseline nAB titers (1:512 and above) (Figure 3C).
373 Nevertheless, in participants who had nAB titers below 1:256 at screening the rate of 4-fold increase
374 of nAB levels was comparable to the seroconversion rates for participants, who were seronegative at
375 screening (85.2% vs. 86.9%, correspondingly, Figure 3D).

376



377

378 **Figure 3.** Seroconversion rates and SARS-CoV-2 neutralizing antibody (nAB) levels in sera of study
 379 participants at different time points post vaccination. SARS-CoV-2 nAB titers (A) and cumulative
 380 seroconversion rate (B) in Vaccine Group and Placebo Group participants who were seronegative at
 381 screening. SARS-CoV-2 nAB titers fold difference from baseline level (C) and cumulative
 382 seroconversion rate (defined as 4-fold increase in the nAB levels) (D) in Vaccine Group and Placebo
 383 Group participants who had detectable nABs at screening at titers <1:256 (N=27), ≤1:256-<1:512
 384 (N=16) or ≥1:512 (N=10). Black line – Mean, whiskers – SD, * – titers at Days 14, 21, 28 and 42
 385 significantly differ from baseline and from Day 7 [p<0.05], ** – the difference between titers at Days
 386 14, 21, 28 and 42 is insignificant [p>0.05].

387


388 Cellular immunity assessment

389 Parameters of cellular immunity were determined for the same 27 randomly selected participants from
 390 the Vaccine Group in Stage 3, who were tested during the assessment of the sensitivity of
 391 commercial CMIA and ELISA tests. Cellular immune response was assessed in whole blood of the
 392 trial participants using QuantiFERON SARS-CoV-2 Starter Set (Qiagen, Germany) by stimulation of

393 IFN- γ production by S-protein-specific CD4 and CD4/CD8 T cells using two SARS-CoV-2 S protein
394 peptide pools (Ag1 and Ag2, respectively). The data is summarized in Figure 4.

395 Compared to baseline levels, we observed a statistically significant ($p < 0.05$) increase of IFN- γ
396 production by peptide-stimulated CD4+ cells of vaccinated participants at Days 14 and 21 after the 1st
397 immunization and a statistically significant increase of combined IFN- γ production by stimulated CD4+
398 and CD8+ cells at Day 21 after the 2nd immunization, indicating the development of both SARS-CoV-
399 2 S protein-specific CD4 helper and CD8 cytotoxic cells.

400



401

402 **Figure 4.** Anti-SARS-CoV-2 cellular immunity test results for randomly selected participants with
403 undetectable SARS-CoV-2 nAB at screening at different time points post vaccination: A) IFN-gamma
404 levels induced by QuantiferON Ag1; B) IFN-gamma levels induced by QuantiferON Ag2
405 Black line – Mean, whiskers – SD, * – difference is significant (Mann-Whitney, $p < 0.05$).

406

407

408 DISCUSSION

409 According to the WHO, by far 18 inactivated vaccines against COVID-19 have passed Phase I-II
410 clinical trials worldwide, of which five have also passed Phase III trials (WHO, 2021). Successful
411 clinical trials of several inactivated vaccines demonstrate that they are highly useful in prevention of
412 severe COVID-19 cases in the situation of drastic global shortage of the COVID-19 vaccines.
413 Previously, the Chumakov Center has successfully developed two inactivated vaccines against tick-
414 borne encephalitis and poliomyelitis produced using Vero cells (Piniaeva et al., 2021; Vorovitch et al.,
415 2020). Therefore, the development of the COVID-19 vaccine CoviVac was based on established cell
416 cultivating platform using previously proven methods. Immunogenicity, safety and protective efficacy
417 of CoviVac has been previously shown in preclinical studies (Kozlovskaya et al., 2021).

418 Here we present the results of a randomized, double-blind, placebo-controlled, multi-center clinical
419 trial of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified
420 coronavirus vaccine CoviVac in adult volunteers aged 18-60.

421 Overall, starting from October 3, 2020, 498 volunteers were screened for eligibility at three clinical
422 sites and 400 volunteers aged 18-60 years were enrolled in the study. All participants were
423 randomized into 2 groups: 300 participants were assigned to receive the vaccine and 100 participants
424 were assigned to receive placebo (2 injections, 0.5 ml, 14 days interval for both the vaccine and
425 placebo).

426 The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events, or
427 other significant AEs related to vaccination have been reported. The most common AE in the Vaccine
428 Group was pain at the injection site. It was registered in the Placebo Group as well, but was
429 significantly less common ($P < 0.05$). One participant (0.3%, 0.1–1.9 95% CI) from the Vaccine Group
430 died at Day 29 of the observation period as a result of acute circulatory disorder, which was not
431 related to the tested vaccine. Autopsy examination revealed signs of chronic mild hepatitis, pre-
432 existing stromal cardiosclerosis and dilated cardiomyopathy manifested by myocardial hypertrophy,
433 which were undetectable by the methods used at pre-vaccination screening.

434 For immunogenicity screening we first assessed the sensitivity of two CMIA used for the detection of
435 anti-SARS-CoV-2 IgG to N and S proteins and two ELISA kits widely used in the diagnostics of
436 SARS-CoV-2 infection, to estimate if their sensitivity is sufficient to detect the post-vaccination
437 antibodies. There was no significant correlation between seropositivity rates assessed by
438 neutralization test (NT) and CMIA (Table 3), although we could see a statistically significant increase
439 in the positivity indices in vaccinated participants who were seronegative at screening. This
440 observation could have several explanations: (1) as the vaccine contains S trimers, nABs can form
441 against other parts of S, not only RBD, (for example, to neutralizing antibody binding domain, 1-319
442 aa), or to nonlinear antigen sites, so, anti-RBD test systems (Beckman) cannot detect them; (2) the
443 vaccine contains N protein, but in lower quantities than is produced during SARS-CoV-2 infection, so
444 anti-N test systems (Abbott) cannot detect them; (3) both CMIA tests measure IgG levels, when,
445 technically, nABs can belong to other classes. As compared to CMIA tests, both ELISA-based

446 antibody detection kits showed higher correlation of seropositivity rates with NT results. Based on
447 these observations, only NT results were used for further calculations of seroconversion rates.

448 In total, immunogenicity assessment was performed by NT in 167 volunteers (122 in Vaccine Group
449 and 45 in Placebo Group) separately for the participants who were anti-SARS-CoV-2 nAB negative
450 (69/122 in Vaccine Group and 28/45 in Placebo Group) or anti-SARS-CoV-2 nAB positive (53/122 in
451 Vaccine Group and 17/45 in Placebo Group) at screening.

452 At Day 42 after the 1st immunization the seroconversion rate in participants who were seronegative at
453 screening was 86.9% with average the nAB GMT of 1:20. However, these nAB levels are above the
454 estimated levels providing protection from symptomatic SARS-CoV-2 infection (Khoury et al., 2021),
455 further protectivity assessment must be performed in Phase III trials.

456 Several studies have shown that antibody responses generated both after vaccination and after
457 SARS-CoV-2 infection can decrease significantly over time (Cho et al., 2021; Prévost et al., 2020;
458 Wang et al., 2020), which would require boosting immunizations in the long term. In this study we
459 show the results of CoviVac immunization in participants with pre-existing anti-SARS-CoV-2
460 antibodies.

461 In this study 'seroconversion' for the participants who were seropositive at screening was defined as
462 4-fold increase in nAB titers compared to baseline. The seroconversion rate for the participants who
463 had NT titers in NT below 1:256 at screening was comparable to that for participants who were
464 seronegative at screening (85.2% and 86.9%, respectively), while in the participants with nAB titers
465 >1:256 the seroconversion rate did not exceed 45%. For the participants who were seropositive at
466 screening the 2nd immunization did not lead to a further significant increase in NT titers. Both facts
467 signify that there is a maximum level of antibodies against SARS-CoV-2, which human immune
468 system can produce, and further antigen addition is useless.

469 The cellular immune response was assessed based on the production of IFN- γ by the CD4+ and
470 CD8+ lymphocytes after stimulation with SARS-CoV-2 S-protein peptide pools. Compared to baseline
471 levels, we observed a statistically significant ($p < 0.05$) increase of IFN- γ production by peptide-
472 stimulated CD4+ cells in vaccinated participants at Days 14 and 21 after the 1st immunization and a
473 statistically significant increase of combined IFN- γ production by stimulated CD4+ and CD8+ cells at
474 Day 21 after the 2nd immunization.

475 In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with 86.9% NT
476 seroconversion rates in participants, who were seronegative at screening. In participants who were
477 seropositive at screening and had nAB titers below 1:256, a single immunization lead to a 4-fold
478 increase in nAB levels in 85.2% cases. These findings indicate that CoviVac can be successfully used
479 both for primary immunization in two-dose regimen and for booster immunization as a single dose in
480 individuals with reduced neutralizing antibody levels.

481

482 **ACKNOWLEDGMENTS**

483 We would like to thank the study participants, the staff of the Research Centres, members of the test
484 management groups, and the staff of Research and Development department of the Chumakov FSC
485 R&D IBP RAS and particularly Vladislav Vasilenko, Konstantin Kaa, Zhad Mazhed, Saglara
486 Sandzhieva, Irina Tcelykh for their contribution in the development of vaccine production process; and
487 Aleksandra Kartseva for help in organizing clinical studies.

488

489 REFERENCES

- 490 Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M. M., Abdulrazzaq, N., ... Yang, X. (2021).
491 Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A
492 Randomized Clinical Trial. *JAMA*, 326(1), 35–45. <https://doi.org/10.1001/JAMA.2021.8565>
- 493 Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... Zaks, T. (2021). Efficacy
494 and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, 384(5),
495 403–416. [https://doi.org/10.1056/NEJMOA2035389/SUPPL_FILE/NEJMOA2035389_DATA-](https://doi.org/10.1056/NEJMOA2035389/SUPPL_FILE/NEJMOA2035389_DATA-SHARING.PDF)
496 SHARING.PDF
- 497 Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., ... Nussenzweig, M.
498 C. (2021). Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA
499 vaccination. *Nature* 2021, 1–6. <https://doi.org/10.1038/s41586-021-04060-7>
- 500 Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., ... Bloom, J. D.
501 (2021). Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory
502 Syndrome Coronavirus 2 Infection. *The Journal of Infectious Diseases*, 223(2), 197–205.
503 <https://doi.org/10.1093/INFDIS/JIAA618>
- 504 Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., ... Vadrevu, K. M. (2021).
505 Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152):
506 interim results of a randomised, double-blind, controlled, phase 3 trial. *The Lancet*.
507 [https://doi.org/10.1016/s0140-6736\(21\)02000-6](https://doi.org/10.1016/s0140-6736(21)02000-6)
- 508 Fadlyana, E., Rusmil, K., Tarigan, R., Rahmadi, A. R., Prodjosoewojo, S., Sofiatin, Y., ...
509 Kartasasmita, C. B. (2021). A phase III, observer-blind, randomized, placebo-controlled study of
510 the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults
511 aged 18–59 years: An interim analysis in Indonesia. *Vaccine*, 39(44), 6520–6528.
512 <https://doi.org/10.1016/j.vaccine.2021.09.052>
- 513 Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., ... Gonzalez-Lopez,
514 A. (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
515 *New England Journal of Medicine*.
516 [https://doi.org/10.1056/NEJMOA2105290/SUPPL_FILE/NEJMOA2105290_DATA-](https://doi.org/10.1056/NEJMOA2105290/SUPPL_FILE/NEJMOA2105290_DATA-SHARING.PDF)
517 SHARING.PDF
- 518 Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., ... Toback, S. (2021).
519 Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *New England Journal of Medicine*,
520 385(13), 1172–1183.
521 [https://doi.org/10.1056/NEJMOA2107659/SUPPL_FILE/NEJMOA2107659_DATA-](https://doi.org/10.1056/NEJMOA2107659/SUPPL_FILE/NEJMOA2107659_DATA-SHARING.PDF)
522 SHARING.PDF
- 523 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., ... Davenport, M.
524 P. (2021). Neutralizing antibody levels are highly predictive of immune protection from
525 symptomatic SARS-CoV-2 infection. *Nature Medicine*, 27(7), 1205–1211.
526 <https://doi.org/10.1038/S41591-021-01377-8>

- 527 Kozlovskaya, L. I., Pinaeva, A. N., Ignatyev, G. M., Gordeychuk, I. V., Volok, V. P., Rogova, Y. V., ...
528 Ishmukhametov, A. A. (2021). Long-term humoral immunogenicity, safety and protective efficacy
529 of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. *Emerging Microbes
530 and Infections*, 10(1), 1790–1806. <https://doi.org/10.1080/22221751.2021.1971569>
- 531 Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., ... Regev-Yochay, G. (2021).
532 Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *New
533 England Journal of Medicine*.
534 [https://doi.org/10.1056/NEJMOA2114583/SUPPL_FILE/NEJMOA2114583_DATA-
535 SHARING.PDF](https://doi.org/10.1056/NEJMOA2114583/SUPPL_FILE/NEJMOA2114583_DATA-SHARING.PDF)
- 536 Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V.,
537 Dzharullaeva, A. S., ... Gintsburg, A. L. (2021). Safety and efficacy of an rAd26 and rAd5 vector-
538 based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised
539 controlled phase 3 trial in Russia. *The Lancet*, 397(10275), 671–681.
540 [https://doi.org/10.1016/S0140-6736\(21\)00234-8/ATTACHMENT/5B392723-A191-4FD1-B36A-
541 F0B5603CA1DD/MMC1.PDF](https://doi.org/10.1016/S0140-6736(21)00234-8/ATTACHMENT/5B392723-A191-4FD1-B36A-F0B5603CA1DD/MMC1.PDF)
- 542 Pinaeva, A., Ignatyev, G., Kozlovskaya, L., Ivin, Y., Kovpak, A., Ivanov, A., ... Ishmukhametov, A.
543 (2021). Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine “PoliovacSin”:
544 Clinical Trials Phase I and II. *Vaccines*, 9(6). <https://doi.org/10.3390/VACCINES9060565>
- 545 Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... Gruber, W. C.
546 (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of
547 Medicine*, 383(27), 2603–2615.
548 https://doi.org/10.1056/NEJMOA2034577/SUPPL_FILE/NEJMOA2034577_PROTOCOL.PDF
- 549 Prévost, J., Gasser, R., Beaudoin-Bussièrès, G., Richard, J., Duerr, R., Laumaea, A., ... Finzi, A.
550 (2020). Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell
551 Reports. Medicine*, 1(7). <https://doi.org/10.1016/J.XCRM.2020.100126>
- 552 Vorovitch, M. F., Grishina, K. G., Volok, V. P., Chernokhaeva, L. L., Grishin, K. V., Karganova, G. G.,
553 & Ishmukhametov, A. A. (2020). Evervac: phase I/II study of immunogenicity and safety of a new
554 adjuvant-free TBE vaccine cultivated in Vero cell culture. *Human Vaccines &
555 Immunotherapeutics*, 16(9), 2123–2130. <https://doi.org/10.1080/21645515.2020.1757990>
- 556 Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., ... Wang, Q. (2020). Neutralizing Antibody
557 Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019
558 Inpatients and Convalescent Patients. *Clinical Infectious Diseases*, 71(10), 2688–2694.
559 <https://doi.org/10.1093/CID/CIAA721>
- 560 WHO. (2021). WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard
561 With Vaccination Data. *Who*. Retrieved from <https://covid19.who.int/>
- 562 Zakarya, K., Kutumbetov, L., Orynbayev, M., Abduraimov, Y., Sultankulova, K., Kassenov, M., ...
563 Khairullin, B. (2021). Safety and immunogenicity of a QazCovid-in® inactivated whole-virion
564 vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-

565 controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in K.
566 *EClinicalMedicine*, 39, 101078. <https://doi.org/10.1016/j.eclinm.2021.101078>
567 Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., ... Zhu, F. (2021). Safety, tolerability, and
568 immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a
569 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious*
570 *Diseases*, 21(2), 181–192. [https://doi.org/10.1016/S1473-3099\(20\)30843-4](https://doi.org/10.1016/S1473-3099(20)30843-4)
571

Screening, N = 498


Stage 1, N = 15






Stage 2, N = 185

Stage 3, N = 200


Immunogenicity
assessment, N = 167

Safety
assessment, N = 398





Participants with undetectable SARS-CoV-2 nABs at screening



Participants with detectable SARS-CoV-2 nABs at screening

